Latest Pharma Insights
Chinese Advanced Molecular Therapy Firms Extend Funding Spree In August
Multiple Chinese ventures including Xianbo, MagicRNA, Siran and Leaderna secure new funding to push ahead with early- or mid-stage clinical studies for their novel assets.
Scrip - September 10, 2026
Multiple Chinese ventures including Xianbo, MagicRNA, Siran and Leaderna secure new funding to push ahead with early- or mid-stage clinical studies for their novel assets.
Scrip - September 10, 2026
Kendal Formula Ad Claims For Superiority, Heritage Put In Context After Abbott Challenge
Kendal says its “whole milk recipe” exclusivity claim, which it withdrew during the review, was accurate when its Kendalmil formula reached US in 2022 during formula supply crisis, but “was removed from the marketplace as soon as new market entrants used this ingredient.”
HBW Insight - September 10, 2026
Kendal says its “whole milk recipe” exclusivity claim, which it withdrew during the review, was accurate when its Kendalmil formula reached US in 2022 during formula supply crisis, but “was removed from the marketplace as soon as new market entrants used this ingredient.”
HBW Insight - September 10, 2026
US Parenteral Nutrient Shortage Prompts ‘Temporary Flexibility’ From FDA To Boost Supply
Potential supply disruption is particularly important because currently there are no FDA-approved starter parenteral nutrition drug products, which include dextrose, amino acids and sometimes calcium and patient-specific formulas.
HBW Insight - September 10, 2026
Potential supply disruption is particularly important because currently there are no FDA-approved starter parenteral nutrition drug products, which include dextrose, amino acids and sometimes calcium and patient-specific formulas.
HBW Insight - September 10, 2026
Chinese Advanced Molecular Therapy Firms Extend Funding Spree In August
Multiple Chinese ventures including Xianbo, MagicRNA, Siran and Leaderna secure new funding to push ahead with early- or mid-stage clinical studies for their novel assets.
Scrip - September 10, 2026
Multiple Chinese ventures including Xianbo, MagicRNA, Siran and Leaderna secure new funding to push ahead with early- or mid-stage clinical studies for their novel assets.
Scrip - September 10, 2026
Seehafer Selection As First Deputy Commissioner Of Technology And AI Draws Praise, Questions
The FDA’s appointment of Jared Seehafer as its first deputy commissioner for technology and AI is attracting a mixed bag of approval and caution. Supporters cite his regulatory and technology experience, while some question his investment background.
Medtech Insight - September 9, 2026
The FDA’s appointment of Jared Seehafer as its first deputy commissioner for technology and AI is attracting a mixed bag of approval and caution. Supporters cite his regulatory and technology experience, while some question his investment background.
Medtech Insight - September 9, 2026
FDA Opens 510(k) Pathway for Eight Device Types
The latest batch of FDA classification orders includes foam that protects reproductive organs during radiation therapy, an ENT robotic platform, and an implant to treat urinary incontinence.
Medtech Insight - September 9, 2026
The latest batch of FDA classification orders includes foam that protects reproductive organs during radiation therapy, an ENT robotic platform, and an implant to treat urinary incontinence.
Medtech Insight - September 9, 2026
Boston Scientific Says Cyberattack Makes 2026 Guidance ‘Unlikely’ To Be Met
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026
UpFront’s Finger-Prick Stroke Blood Test Gets First-Of-Its-Kind CE Mark
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026
Kendal Formula Ad Claims For Superiority, Heritage Put In Context After Abbott Challenge
Kendal says its “whole milk recipe” exclusivity claim, which it withdrew during the review, was accurate when its Kendalmil formula reached US in 2022 during formula supply crisis, but “was removed from the marketplace as soon as new market entrants used this ingredient.”
HBW Insight - September 10, 2026
Kendal says its “whole milk recipe” exclusivity claim, which it withdrew during the review, was accurate when its Kendalmil formula reached US in 2022 during formula supply crisis, but “was removed from the marketplace as soon as new market entrants used this ingredient.”
HBW Insight - September 10, 2026
US Parenteral Nutrient Shortage Prompts ‘Temporary Flexibility’ From FDA To Boost Supply
Potential supply disruption is particularly important because currently there are no FDA-approved starter parenteral nutrition drug products, which include dextrose, amino acids and sometimes calcium and patient-specific formulas.
HBW Insight - September 10, 2026
Potential supply disruption is particularly important because currently there are no FDA-approved starter parenteral nutrition drug products, which include dextrose, amino acids and sometimes calcium and patient-specific formulas.
HBW Insight - September 10, 2026
The Generics Bulletin Podcast: Discussing Sandoz’s Strategy As It Prepares For A Biosimilars Boom
Sandoz’s Bio100 strategy sets out the firm’s ambition to have more than 100 biosimilars in its portfolio by 2040 and more than double sales from 2025 to 2035. Fresh from the announcement at the London Stock Exchange, Generics Bulletin editors Dave Wallace and Dean Rudge discusses the key aspects.
Generics Bulletin - September 9, 2026
Sandoz’s Bio100 strategy sets out the firm’s ambition to have more than 100 biosimilars in its portfolio by 2040 and more than double sales from 2025 to 2035. Fresh from the announcement at the London Stock Exchange, Generics Bulletin editors Dave Wallace and Dean Rudge discusses the key aspects.
Generics Bulletin - September 9, 2026
Updated US FDA Therapeutic Equivalence Guidance Allows Faster 505(b)(2) Rating Requests
505(b)(2) sponsors now may request a therapeutic equivalence rating when their product's inactive ingredients differ from the reference listed drug.
Generics Bulletin - September 9, 2026
505(b)(2) sponsors now may request a therapeutic equivalence rating when their product's inactive ingredients differ from the reference listed drug.
Generics Bulletin - September 9, 2026
Rivastigmine Rises Dominate UK Increases In August
Multiple presentations of rivastigmine capsules saw their UK trade prices more than double in August, according to the latest figures from WaveData.
Generics Bulletin - September 9, 2026
Multiple presentations of rivastigmine capsules saw their UK trade prices more than double in August, according to the latest figures from WaveData.
Generics Bulletin - September 9, 2026
Bonus Podcast: ZS On How Patients Are Changing Their Own Journeys With AI
Patients are increasingly empowered by the ability to use AI to control their healthcare journeys. A landmark three-country survey by ZS noted how this trend was becoming generalized. ZS’ Jon Roffman and Bhargav Mantha highlight how traditional healthtech and pharma industries must react.
In Vivo - September 9, 2026
Patients are increasingly empowered by the ability to use AI to control their healthcare journeys. A landmark three-country survey by ZS noted how this trend was becoming generalized. ZS’ Jon Roffman and Bhargav Mantha highlight how traditional healthtech and pharma industries must react.
In Vivo - September 9, 2026
Dealmaking Quarterly Statistics, Q2 2026
During Q2, biopharma merger and acquisition deal value reached $92.6bn and drew in $82.3bn in potential deal value from alliances. Device company M&A values reached $4.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $14.5bn.
In Vivo - September 9, 2026
During Q2, biopharma merger and acquisition deal value reached $92.6bn and drew in $82.3bn in potential deal value from alliances. Device company M&A values reached $4.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $14.5bn.
In Vivo - September 9, 2026
The Company Betting It Can Simulate A Human Body
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026